BEIJING: Chinese vaccine producers are accelerating clinical trials for COVID-19 vaccine candidates and preparing for full-speed production once a product is approved to enter the market.
A phase III clinical trial project on a COVID-19 vaccine jointly developed by Chinese company CanSino Biologics Inc (CanSinoBIO) and military infectious expert Chen Wei was launched on Tuesday in Pakistan, following another phase III clinical trial on the vaccine starting in Russia.
According to Pakistan newspaper Dawn, around 8,000 to 10,000 volunteers in the country will participate in the project and initial results of the trial are expected in four to six months. Meanwhile, clinical trials on the CanSinoBIO vaccine are being held in seven countries, including Pakistan, covering a total of 40,000 people.
As the company that developed China’s first COVID-19 vaccine to enter clinical trials, released the world’s first COVID-19 vaccine clinical trial data and obtained the first patent for COVID-19 in China, CanSino said they are now accelerating international clinical trials to test the efficacy of the vaccine and lay out mass production.
On August 31, CanSinoBIO signed an agreement with Shanghai Pharmaceuticals Holdings Co. Ltd. to cooperate on vaccine research and development, production and storage to guarantee vaccine supply. Solution Biologics Sdn Bhd, a subsidiary under Malaysian investment holding company Solution Group Berhad, is also reportedly talking with CanSinoBIO to promote registration, production and marketization of CanSinoBIO’s COVID-19 candidate vaccine in Malaysia.
– The Daily Mail-Global Times News exchange item
